These mutations were associated with the activation of the mTOR pathway in colorectal cancer, endometroid carcinoma, stomach cancer, lung carcinoma, renal cell carcinoma (RCC), and melanoma.86 This study displayed that mTOR mutations were clustered in six distinct regions in the c-terminal part of mTOR in human tumors. This evidence concerns the gene MTOR and melanoma.